Cytokine-mediated enhancement of epidermal growth factor receptor expression provides an immunological approach to the therapy of pancreatic cancer

Por Schmiegel, Wolff, Schmielau, Jan, Henne-Bruns, Doris, Juhl, Hartmut, Roeder, Christian, Buggisch, Peter, Onur, Aydin, Kremer, Bernd, Kalthoff, Holger, Jensen, Elwood V.
Publicado em 1997

The transhepatic endotoxin gradient is present despite liver cirrhosis and is attenuated after transjugular portosystemic shunt (TIPS).

Por Lohse Ansgar W, Franco Veronica, Won Helen, Gaydos Charlotte A, Böger Rainer H, Buggisch Peter, Koops Andreas, Sydow Karsten, Wiesch Julian, Benten Daniel, Ray Stuart C, Balagopal Ashwin
Publicado em 2011-10-01

The transhepatic endotoxin gradient is present despite liver cirrhosis and is attenuated after transjugular portosystemic shunt (TIPS).

Por Benten, Daniel, Wiesch, Julian Schulze zur, Sydow, Karsten, Koops, Andreas, Buggisch, Peter, Böger, Rainer H, Gaydos, Charlotte A, Won, Helen, Franco, Veronica, Lohse, Ansgar W, Ray, Stuart C, Balagopal, Ashwin
Publicado em 2011

An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1)

Por Asselah, Tarik, Moreno, Christophe, Sarrazin, Christoph, Gschwantler, Michael, Foster, Graham R., Craxí, Antonio, Buggisch, Peter, Ryan, Robert, Lenz, Oliver, Scott, Jane, Van Dooren, Gino, Lonjon-Domanec, Isabelle, Schlag, Michael, Buti, Maria
Publicado no PLoS One (2016)

Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate...

Por Asselah, Tarik, Moreno, Christophe, Sarrazin, Christoph, Gschwantler, Michael, Foster, Graham R., Craxí, Antonio, Buggisch, Peter, Sanai, Faisal, Bicer, Ceyhun, Lenz, Oliver, Van Dooren, Gino, Nalpas, Catherine, Lonjon-Domanec, Isabelle, Schlag, Michael, Buti, Maria
Publicado no PLoS One (2017)

Vitamin D Levels Vary during Antiviral Treatment but Are Unable to Predict Treatment Outcome in HCV Genotype 1 Infected Patients

Por Grammatikos, Georgios, Lange, Christian, Susser, Simone, Schwendy, Susanne, Dikopoulos, Nektarios, Buggisch, Peter, Encke, Jens, Teuber, Gerlinde, Goeser, Tobias, Thimme, Robert, Klinker, Hartwig, Boecher, Wulf O., Schulte-Frohlinde, Ewert, Penna-Martinez, Marissa, Badenhoop, Klaus, Zeuzem, Stefan, Berg, Thomas, Sarrazin, Christoph
Publicado em 2014

Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection

Por Bourgeois, Stefan, Van Vlierberghe, Hans, Moreno, Christophe, Orlent, Hans, Nevens, Frederik, Arastéh, Keikawus, Horsmans, Yves, Schattenberg, Jörn M., Buggisch, Peter, Francque, Sven, Vijgen, Leen, Kakuda, Thomas N., Hoeben, Eva, Luo, Donghan, Vandebosch, An, Jacquemyn, Bert, Van Remoortere, Pieter, Verloes, René
Publicado no BMC Gastroenterol (2017)

Treatment of Naïve Patients with Chronic Hepatitis C Genotypes 2 and 3 with Pegylated Interferon Alpha and Ribavirin in a Real World Setting: Relevance for the New Era of DAA

Por Heidrich, Benjamin, Wiegand, Steffen B., Buggisch, Peter, Hinrichsen, Holger, Link, Ralph, Möller, Bernd, Böker, Klaus H. W., Teuber, Gerlinde, Klinker, Hartwig, Zehnter, Elmar, Naumann, Uwe, Busch, Heiner W., Maasoumy, Benjamin, Baum, Undine, Hardtke, Svenja, Manns, Michael P., Wedemeyer, Heiner, Petersen, Jörg, Cornberg, Markus
Publicado em 2014

Preclinical Profile and Clinical Efficacy of a Novel Hepatitis C Virus NS5A Inhibitor, EDP-239

Por Owens, Christopher M., Brasher, Bradley B., Polemeropoulos, Alex, Rhodin, Michael H. J., McAllister, Nicole, Peng, Xiaowen, Wang, Ce, Ying, Lu, Cao, Hui, Lawitz, Eric, Poordad, Fred, Rondon, Juan, Box, Terry D., Zeuzem, Stefan, Buggisch, Peter, Lin, Kai, Qiu, Yao-Ling, Jiang, Lijuan, Colvin, Richard, Or, Yat Sun
Publicado no Antimicrob Agents Chemother (2016)